LIfT Biosciences develops Immuno-Modulatory Alpha Neutrophils (IMANs), a first-in-class allogeneic innate cell therapy designed to directly kill cancer cells while enhancing the immune system's ability to identify and eliminate tumors. This dual mechanism addresses the challenge of insufficient immune response in cancer treatment, aiming to improve patient outcomes in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer treatments struggle with insufficient immune response, leading to limited effectiveness in identifying and eliminating tumors. Current therapies often fail to fully engage the immune system to target cancer cells effectively.
Solution
LIfT Biosciences develops Immuno-Modulatory Alpha Neutrophils (IMANs), an allogeneic innate cell therapy engineered to directly kill cancer cells and simultaneously enhance the immune system's ability to recognize and destroy tumors. IMANs act as immuno-surveillance cells, designed with a dual mechanism-of-action to overcome the limitations of existing cancer treatments. By directly targeting cancer cells and modulating the broader immune response, IMANs aim to improve patient outcomes in oncology. This approach leverages the innate immune system to provide a more robust and targeted anti-cancer effect.
Target Audience
The primary target audience includes oncology patients with solid tumors and hematological malignancies, as well as clinicians seeking novel immunotherapeutic approaches.
Features
- Allogeneic "off-the-shelf" cell therapy, enabling immediate treatment availability
- Dual mechanism-of-action: direct cancer cell killing and immune system modulation
- Neutrophil-based immunotherapy, harnessing the innate immune system
- Designed to enhance tumor recognition and elimination by the immune system